Syllable Funding: How Much Did They Raise & Key Investors

How Much Did Syllable Raise?
Funding & Key Investors

Syllable, a prominent player in the healthcare technology sector, has successfully secured significant capital to accelerate its mission of optimizing patient-provider communication. The company's total funding trajectory, culminating in a $81.7M valuation milestone, reflects robust investor confidence in its AI-driven infrastructure. Most recently, the firm closed a $40M round, marking a major strategic investment that underscores its transition from a scaling startup to an enterprise-level healthcare solution provider.

This latest infusion of capital serves as a testament to the market demand for intelligent automation in clinical settings. By leveraging advanced voice and web-based assistants, Syllable is effectively bridging the communication gap between patients and hospital systems, ensuring that administrative burdens are reduced while patient engagement is prioritized.

What is Syllable?

Syllable

Software

Healthcare Software

Business Services

Headquartered in San Jose, California, Syllable operates at the intersection of artificial intelligence and healthcare services. The company specializes in developing sophisticated voice and web assistant platforms designed to streamline the patient experience. By automating routine inquiries and appointment scheduling, Syllable enables healthcare organizations to improve operational efficiency and patient satisfaction. Its market position is defined by its ability to integrate seamlessly into existing hospital workflows, providing a scalable digital front door that addresses the complexities of modern healthcare delivery.

How much funding has Syllable raised?

Syllable has raised a total of $81.7M across 3 funding rounds:

2018

Series A

$13.7M

2021

Series B

$28M

2022

Series C

$40M

Series A (2018): $13.7M, investors not publicly disclosed

Series B (2021): $28M led by Oak HC/FT and Section 32

Series C (2022): $40M supported by Oak HC/FT, The TCV, Section 32, and Verily

Key Investors in Syllable

Oak HC/FT

A premier venture growth-equity fund focused on driving transformation in healthcare and financial services through strategic counsel and board-level participation.

Section 32

A venture capital firm founded by Bill Maris that targets innovative startups and emerging technologies to support visionary entrepreneurs.

Verily

A subsidiary of Alphabet Inc. focused on improving health outcomes through data-driven research, analytics tools, and digital health solutions.

What's next for Syllable?

With the recent influx of capital, Syllable is well-positioned to expand its enterprise footprint and enhance its core AI capabilities. The strategic focus will likely center on deepening its integration with electronic health records and scaling its deployment across larger health systems. As the healthcare industry continues to prioritize digital transformation, Syllable's ability to provide reliable, data-driven communication tools will be critical. Investors are clearly betting on the company's potential to become a foundational layer in the digital health ecosystem, driving long-term value through improved clinical outcomes and reduced administrative overhead.

See full Syllable company page

See More Financial Insights